

116TH CONGRESS
2D SESSION

H. R. 6609

To provide for the immediate procurement of COVID–19 medical testing components, materials, and supplies under the Defense Production Act of 1950.

IN THE HOUSE OF REPRESENTATIVES

APRIL 23, 2020

Mr. PANETTA (for himself, Mr. BROWN of Maryland, Ms. JUDY CHU of California, Mr. CISNEROS, Mr. DEFazio, Mr. ESPAILLAT, Ms. GABBARD, Mr. GRIJALVA, Mr. HASTINGS, Mr. HUFFMAN, Mr. KILMER, Mr. LOEBSACK, Mr. MALINOWSKI, Mr. SEAN PATRICK MALONEY of New York, Ms. MENG, Mr. NADLER, Mrs. NAPOLITANO, Ms. NORTON, Mr. PAYNE, Mr. PHILLIPS, Miss RICE of New York, Mr. RUPPERSBERGER, Mr. RUSH, Mr. SCHNEIDER, Ms. SEWELL of Alabama, Mr. SIRES, Ms. SPANBERGER, Mr. SUOZZI, and Mr. VELA) introduced the following bill; which was referred to the Committee on Financial Services

A BILL

To provide for the immediate procurement of COVID–19 medical testing components, materials, and supplies under the Defense Production Act of 1950.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Immediate COVID
5 Testing Procurement Act.”

1 **SEC. 2. IMMEDIATE PURCHASE ORDERS OF COVID-19 MED-**
2 **ICAL TESTING COMPONENTS, MATERIALS,**
3 **AND SUPPLIES.**

4 (a) **IN GENERAL.**—Not later than 24 hours after the
5 date of the enactment of this Act, the President shall issue
6 any necessary purchase orders for a program of the high-
7 est national urgency (commonly known as a “DX” pur-
8 chase order) pursuant to Department of Defense Directive
9 4400.1 to procure all necessary components, materials,
10 and supplies to conduct molecular and serological
11 COVID-19 medical testing nationwide under authorities
12 provided by the Defense Production Act of 1950 (50
13 U.S.C. 4501 et seq.).

14 (b) **APPROVAL OR AUTHORIZATION.**—All compo-
15 nents, materials, and supplies described in subsection (a)
16 must have received prior approval of the Center for Dis-
17 ease Control and Prevention or have received emergency
18 use authorization from the Food and Drug Administration
19 for the detection of coronavirus disease 2019 (commonly
20 known as “COVID-19”).

21 (c) **WAIVER OF REQUIREMENTS RELATING TO**
22 **SHORTFALLS AND NOTIFICATIONS.**—The requirements of
23 sections 301(d)(1)(A) and 303(a)(6) of the Defense Pro-
24 duction Act of 1950 (50 U.S.C. 4531(d)(1)(A);
25 4533(a)(6)) are waived for purposes of this section.

1 (d) FUNDING.—Amounts available in the Defense
2 Production Act Fund (established under section 304 of
3 the Defense Production Act of 1950 (50 U.S.C. 4534))
4 shall be made available for purchases made under this sec-
5 tion.

○